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1. Introduction 
Glucose 1,6-diphosphate (Glc-1 ,6-PZ) was first 
shown [l-3] to be the coenzyme in the phospho- 
glucomutase reaction. Our experiments have revealed 
that this compound acts also as a deinhibitor of phos- 
phoglucomutase [4-71. Glc-1,6-P, has also been 
reported [8-lo] to be one of the strongest 
deinhibitors of phosphofructokinase, the rate-limiting 
enzyme in glycolysis. Studies [4,7,1 l] have revealed 
that Glc-I ,6-P, exerts a potent inhibitory action on 
muscle hexokinase. We have also shown that the levels 
of this regulator in muscle fluctuate under different 
physiological and hormonal conditions [7,12-141, 
leading to concomitant changes in the activities of the 
enzymes which are regulated by this modulator. All 
these experiments show that Glc-1,6-P, is a powerful 
regulator of glucose metabolism in muscle. The 
regulatory action of Glc-1,6-P* is not limited to 
muscle. This compound also plays an important role 
in the regulation of red cell glycolysis through its 
potent effects on the key glycolytic enzymes 
(reviewed [ 151). 
In [ 161 we found a striking decrease in the levels 
of Glc-1,6-P, in dystrophic muscle, which was 
associated with a marked reduction in the activity of 
phosphofructokinase. These findings prompted us to 
examine whether the reduction in Glc-1,6-P? in the 
dystrophic muscle is also associated with correlated 
changes in other enzymes which are affected by this 
regulator. The results here show that such correlation 
does indeed exist, reflecting the pathological changes 
in glucose metabolism in the dystrophic muscle. 
2. Methods 
Normal and genetically dystrophic mice of strain 
129 ReJ, aged 8-12 weeks (except where otherwise 
indicated) were used. The animals were anesthetized 
with sodium pentobarbital, hind-leg muscles were 
rapidly removed and frozen between a pair of alumi- 
nium tongs pre-cooled in liquid Nz . Frozen muscle was 
powdered in a mortar cooled in liquid N2 and the 
powder used for extraction of Glc-1,6-P, and enzymes. 
Glc-1,6-P? was extracted as in [7], except that 
only 40-70 mg frozen powder was used. Glc-1 ,6-PZ 
was measured by the fluorometric method in [ 171. 
Hexokinase was extracted and assayed fluorometri- 
tally as in [7]. 1 mU hexokinase represents the 
amount of enzyme activity which forms 1 nmol 
NADPH in 1 min at 25°C. Phosphoglucomutase was 
extracted and assayed as in [7], except that ATP was 
not added to the extraction buffer. 1 mU phospho- 
glucomutase activity catalyzed the reduction of 
1 nmol NADP’/min at 25°C. 6-Phosphogluconate 
dehydrogenase was extracted by homogenizing 
-100 mg frozen tissue powder in 4 vol. cold 0.05 M 
Tris-HCl buffer (pH 7.4) for 30 s in an ice bath using 
a Willems-Polytron homogenizer at a setting of 4. The 
homogenates were centrifuged at 27 000 X g at 4°C 
for 20 min. Activity was assayed in a reaction mix- 
ture which consisted of: 0.05 M Tris-HCl (pH 7.6) 
1 mM Mg-acetate, 5 PM 6-phosphogluconate, 12.5 PM 
NADP+, and lo-25 4 muscle extract, in final vol. 
2.0 ml. Fluorescence of NADPH was read in Perkin 
Elmer (MPF-44) fluorescence spectrophotometer. 
1 mU 6-phosphogluconate dehydrogenase represents 
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the amount of enzyme activity which forms 1 nmol 
NADPH in 1 min at 25°C. Controls in which NADP* 
was omitted, were recorded for each experiment. 
Protein was measured by the method in [ 181 with 
crystalline bovine serum albumin as a standard. 
Noncollagen protein was determined by the method 
in [19]. 
3. Results 
We have found [ 161 that the levels of Glc-1 ,6-P2 
in the muscle tissue of dystrophic mice, between 7 
and 8 weeks of age, is reduced to 46% that of normal 
mice. In the experiments shown in table 1 we measured 
the concentration of this regulator in dystrophic and 
normal muscle at two stages of the disease, in mice 
aged 4 weeks, when the first signs of muscle weakness 
are observed, and in mice aged 12 weeks. The results 
Table 1 
Glucose 1,6diphosphate levels in normal and 
dystrophic muscle 
C&-1,6-P, (~moljkg wet wt) 
Mice aged 4 weeks Mice aged 12 weeks 
Normal 35.1 f 1.4 (5) 42.6 t 0.8 (5) 
Dystrophic 21.1 * 2.0 (5) 17.6 f 1.8 (5) 
% of normal 60 41 
P value <O.OOl <O.OOl 
Preparation of muscles, extraction and measurements of
Glc-1,6-P, were as in section 2. Values are means t SEM, 
with no. expts in parentheses 
show a significant decrease in Glc-1 ,6-PZ level in the 
dystrop~c muscle at 4 weeks and a slightly greater 
decrease at 12 weeks of age. The fact that the reduc- 
tion in the Glc-1,6-P, levels occurs in the early stages 
of the disease, suggests hat these changes may be 
primary and not secondary in relation to the dys- 
trophic process. 
Since Glc-1 ,6-PZ is a potent activator of muscle 
phosphoglucomutase nd an inhibitor of muscle hexo- 
kinase, we examined whether a correlation exists 
between the reduction in the levels of Glc-1,6-P, 
in the dystrophic muscle and the activities of these 
enzymes. The experiments shown in table 2 reveal 
that conco~tant to the decrease in Glc-1,6-P,, the 
activity of phospho~ucomutase in dystrophic muscle 
was significantly reduced (whether expressed per mg 
protein or per mg non-collagen protein), whereas that 
of hexokinase was enhanced. Thus the activities of 
both enzymes correlate to the changes in the levels of 
Glc-1,6-P, which occur in the disease. Figure 1 shows 
that hexokinase from dystrophic muscle is extremely 
sensitive to inhibition by Glc-1,6-P,. 
The fact that the decrease in Glc-1,6-P, levels in 
the dystrophic muscle is associated with correlated 
changes in the activities of all three enzymes which 
are regulated by this modulator, namely, phospho- 
fructokinase [ 1.61, phosphoglucomuta~ nd hexo- 
kinase (table 2), strongly suggests hat the decrease in
the tissue levels of Glc-1 ,6-PZ affects these activities. 
Since our recent experiments (unpublished ata) 
have revealed that Glc-1,6-P* is also a potent inhibitor 
of mammalian and yeast (Sigma) 6-phosphogluconate 
dehydrogenase, wemeasured the activity of this 
enzyme in the muscle of normal and dystrophic mice. 
Table 2 
Pho~ho~ucomu~se and hexokhmse activities in normal and dystrophic muscle 
Phosphoglucomutase activity Hexokinase activity 
mU/mg protein mU/mg NCPa mU/mg protein mU/mg NCPa 
Normal 366 f 24 (7) 512 * 34 (7) 4.23 * 0.21 (17) 5.99 * 0.36 (15) 
Dystrophic 208 + 22 (8) 327 + 19 (8) 6.14 f 0.50 (17) 9.18 f 0.75 (15) 
% of normal 57 64 145 153 
P value <0.0005 <O.OOl <O.OOl <O.OOl 
a NCP, non-collagen protein 
Enzymes were extracted and assayed as in section 2. Values are means * SEM, with no. expts 
in parentheses 
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GLUCOSE-1,6-P* (pM) 
Fig.1. The inhibitory effect of G&1,6-P, on the activity of 
hexokinase from dystrophic muscle. Hexokinase was prepared 
from muscles of dystrophic mice and assayed as in section 2. 
Assays were carried out in the presence of variable Glc-1,6-P, 
concentrations. 100% hexokinase activity refers to 7.2 mU/mg 
protein. Vertical bars represent SEM for 4-6 expts. 
The results ummarized in table 3 show a striking 
elevation of the activity of this enzyme in the dys- 
trophic muscle. Figure 2 shows that 6.phospho~uconate 
dehydrogenase from dystrop~c muscle is extremely 
sensitive to inhibition by Glc-1,6-P,. Thus the reduc- 
tion in the level of this inhibitor in dystrophic muscle 
(table 1) may most probably account, at least partially, 
for the activation of this enzyme. 
4. Discussion 
Previous tudies from this laboratory have revealed 
that the Glc-1,6-P, levels in muscle fluctuates under 
Table 3 
The activity of 6~ho~hoglu~nate dehydrogena~ in normal 
and dystrophic muscle 
6-Phosphogluconate dehydrogenase 
mU/mg protein mU/mg NCPa 
Normal 2.16 f 0.18 (6) 2.90 * 0.26 (5) 
Dystrophic 5.62 f. 0.61 (8) 7.48 * 1.30 (6) 
% of normal 260 258 
P value <0.0005 co.02 
a NCP, NoncoLlagen protein 
The enzyme was extracted and assayed as in section 2. Values 
are means f SEM, with no. expts in parentheses 
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GLUCOSE-l,6-P2 (/AM) 
Fig.2. The inhibitory effect of Glc-1,6-P, on the activity of 
6-phosphogluconate dehydrogenase from dystrophic muscle. 
The enzyme was extracted from muscles of dystrophic mice 
and assayed as in section 2. Assays were carried out at vari- 
able Glc-1,6-P, concentrations. 100% activity refers to 
5.9 mU/mg protein. Values are means f SEM for 4-6 expts. 
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